Oxotremorine-induced cholinergic syndrome: modifications by levodopa and/or oral cytidine diphosphocholine.
A peripheral and cerebral cholinergic syndrome was induced in mice by oxotremorine administration; pretreatment orally with cytidine diphosphocholine (CDP-choline) does not potentiate this syndrome and even antagonizes oxotremorine-induced salivation. Levodopa antagonizes the oxotremorine-induced cerebral symptoms (akinesia + tremor); however this antagonism disappears when mice are chronically pretreated orally with CDP-choline, confirming the action of CDP-choline on dopaminergic pathways. The proven efficacy of CDP-choline in Parkinsonism could then be mediated by a hypersensitivity of some cerebral dopamine receptors, and not by a direct stimulating effect of the striatal dopaminergic receptors.
D000284:Administration, Oral; D000818:Animals; D002794:Choline / Q000031:analogs & derivatives*; D003566:Cytidine Diphosphate Choline / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D003967:Diarrhea / Q000139:chemically induced / Q000188:drug therapy; D005260:Female; D007035:Hypothermia / Q000139:chemically induced / Q000188:drug therapy; D007980:Levodopa / Q000494:pharmacology* / Q000627:therapeutic use; D051379:Mice; D010095:Oxotremorine / Q000037:antagonists & inhibitors*; D012472:Salivation / Q000187:drug effects; D013577:Syndrome; D014202:Tremor / Q000139:chemically induced / Q000188:drug therapy
D007980:Levodopa; D003566:Cytidine Diphosphate Choline; D010095:Oxotremorine; D002794:Choline